6:30 PM Registration and Dinner
7:00 PM Welcome and Introduction
7:05 PM Rationale and Overview of Immuno-Oncology in RCC
7:15 PM Patient Case Examples With Panel Discussion and Audience Q&A
- Planning First-Line Treatment for Patients with Favorable-Risk Advanced RCC - M. Dror Michaelson, MD, PhD
- Choosing First-Line Treatment for Patients with Intermediate/Poor-Risk Advanced RCC - Martin H. Voss, MD
- Optimal Treatment for Patients with RCC After Previous Therapy - Elizabeth R. Plimack, MD, MS
- Management of Immune Related AEs for Advanced RCC - Elizabeth R. Plimack, MD, MS
8:50 PM Final Thoughts and Audience Q&A Session
Date / Time
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
M. Dror Michaelson, MD, PhD
Associate Professor of Medicine
Massachusetts General Hospital Cancer Center
Martin H. Voss, MD
Assistant Attending, Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data, expert recommendations, and guidelines to optimize the use of immuno-oncology-based combinations in the care of their patients with RCC.
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with RCC.
Upon completion of this activity, participants should be able to:
- Describe the rationale for combining immune checkpoint inhibitors with another immune checkpoint inhibitor or VEGFR TKIs for the treatment of RCC
- Identify patients most likely to benefit from immune checkpoint inhibitor-based combination therapy based on risk assessment, along with patient medical and treatment history
- Plan optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
- Apply clinical evidence and expert recommendations to select optimal treatment for patients with progressive RCC after 1 or more previous lines of therapy
- Plan therapeutic strategies that optimize the sequence of therapies to provide the best outcome to patients with RCC
- Manage specific disease-related complications and treatment or immune-related adverse events associated with IO and IO combinations for advanced RCC
Joint Accreditation Statement
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation of Credit
Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistant Continuing Education
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Education
NCCN designates this educational activity for a maximum of 2.0 contact hours.
Pharmacist Continuing Education
NCCN designates this application-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. UAN: JA4008196-0000-20-020-L01-P
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.